ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "naproxen"

  • Abstract Number: 1439 • 2016 ACR/ARHP Annual Meeting

    The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants

    Marije I. Koenders1, Monique M. Helsen1, Birgitte Walgreen1, Wim B. van den Berg1, Gianfranco Caselli2, Ornella Letari2 and Peter M. van der Kraan1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Rottapharm Biotech, Monza, Italy

    Background/Purpose: CR6086 is a novel small molecule acting as a potent and selective antagonist of the prostaglandin E2 (PGE2) receptor EP4 subtype (EP4 receptor). Recent…
  • Abstract Number: 1439 • 2015 ACR/ARHP Annual Meeting

    Reducing Gastric Ulcers in Patients with a History of Gastrointestinal (GI) Ulcers Who Require Long-Term High-Dose Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy

    John Fort1, Robert J. Holt2, Jeffrey D. Kent3 and Alfonso Bello4, 1POZEN Inc., Chapel Hill, NC, 2College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, 3Horizon Pharma USA, Inc., Deerfield, IL, 4Illinois Bone & Joint Inst, Glenview, IL

     Background/Purpose: Patients ≥65 taking naproxen with previous GI symptoms have a 29% annual incidence of significant upper gastrointestinal events.(1) Those patients who are older, with…
  • Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting

    Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis

    J Sieper1, M Rudwaleit1, J Lenaerts2, J Wollenhaupt3, L Myasoutova4, S Park5, Y Song6, R Yao7, M Govoni8, D Chitkara9 and N Vastesaeger10, 1University Clinic Benjamin Franklin, Berlin, Germany, 2Practice Rheumatology, Hasselt, Belgium, 3Schön-Klinik, Hamburg, Germany, 4Kazan State Medical University, Kazan, Russia, 5Catholic University of Korea, Seoul, South Korea, 6Seoul National University, Seoul, South Korea, 7Merck & Co., Inc., Whitehouse Station, NJ, 8MSD Italy, Rome, Italy, 9Merck Sharp & Dohme, Kenilworth, NJ, 10Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.